Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of ...

The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data ...

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025.The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected ...

Oppenheimer Asset Management Inc. lessened its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 6.2% in ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) stands against other best ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of ...

Ogsiveo's net product revenues were $172 million in 2024. Last month, the FDA approved SpringWorks’ MEK inhibitor, Gomekli (mirdametinib) for the treatment of adult and pediatric patients 2 ...